Daclatasvir (Standard)
Based on 1 publication(s) in Google Scholar
Daclatasvir (Standard) is the analytical standard of Daclatasvir. This product is intended for research and analytical applications. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively.
For research use only. We do not sell to patients.
- CAS No.: 1009119-64-5
- Formula: C40H50N8O6
- Molecular Weight:738.88
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Daclatasvir (Standard)
More
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 1009119-64-5
-
Molecular Weight 738.88
-
Formula C40H50N8O6
-
SMILES
O=C([C@@H](NC(OC)=O)C(C)C)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C5=CN=C([C@@H]6CCCN6C([C@@H](NC(OC)=O)C(C)C)=O)N5)C=C4
-
Synonyms
BMS-790052 (Standard); EBP 883 (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Anal Chim Acta
Comprehensive investigation of matrix effect evaluation approaches for reliable quantification in bioanalysis using UHPLC-MS/MS. [Abstract]2026 Sep 1:1413:345642. PMID: 42230010
Purity & Documentation
References
[1]. Min Gao, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010 May 6;465(7294):96-100. [Content Brief]
[2]. David B Ascher, et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014 Apr 23;4:4765. [Content Brief]
[3]. Tomomi Furihata, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014 Aug;58(8):4555-64. [Content Brief]
[4]. Seung-Hoon Lee, et al. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep. 2018 Aug 20;8(1):12469. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)